BRIDGING INNOVATION AND ACCESS: A GLOBAL PERSPECTIVE ON ORPHAN DRUG DEVELOPMENT AND CHALLENGES IN TREATING RARE DISEASES

Orphan drugs are a category of pharmaceuticals specifically designed for the treatment of rare diseases. They therefore represent an important unmet need within global healthcare systems. Rare diseases are typically defined by low prevalence: less than 5 per 10,000 people in the EU or less than 200,000 in the US. These diseases severely affect the quality of life of the patients but gain much less attention because of their low commercial viability. There have also been regulatory frameworks, such as the United States Orphan Drugs Act of 1983 and the European Union Regulation (EC) No 141/2000, among others, that encouraged research and development by offering market exclusivity, fiscal incentives, and accelerated approval processes. Challenges abound, however. The high cost of orphan drugs is often traced to the paucity of patients, cumbersome clinical trial regulations, and limited earnings from the small market. Thus, the novel treatments are expensive and put a burden on health infrastructures and make them less accessible, particularly in developing countries. Promising interventions, such as gene-editing therapies, exemplified by Zolgensma, demonstrate their potential while underlining the need for fair pricing models. Recent developments in this area include the advancements in gene and stem cell therapies, small nucleic acid pharmaceuticals, and RNA-based treatments. Collaborative approaches, including public partnerships and global research networks, accelerate progress in therapeutic interventions. However, unequal access is an issue that calls for political reforms, financial incentives, and adaptive pricing strategies. Pharmaceutical development for rare diseases is of great importance in the future. It regulates flexibility and global cooperation and bases its efforts on the implementation of scientific discoveries that make innovation accessible. Overcoming financial, ethical, and social barriers to the production of drugs for orphan diseases is necessary to ensure fair treatment for 300 million people worldwide who suffer from rare diseases.